All In Biotech

NDA 206256 · Acrotech Biopharma

Beleodaq

Belinostat · Intravenous · Histone Deacetylase Inhibitor

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jul 3, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

57

2 Phase 3, 4 recruiting

FAERS reports

358

318 serious, 121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2025.

Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see Clinical Studies ( 14 )]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.( 1 )

Mechanism: Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro , belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 3, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelSummary ReviewReview
1 products under this application
  • BELEODAQ · BELINOSTAT 500MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Belinostat" as an intervention, any sponsor and status, largest first.

All 57 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • disease progression77
  • nausea59
  • anaemia49
  • death43
  • vomiting43
  • dyspnoea36
  • platelet count decreased33
  • fatigue32
  • constipation28
  • neutropenia26
  • diarrhoea25
  • white blood cell count decreased24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20113
20131
201410
201512
20165
20176
20186
201912
202014
202170
202249
202357
202440
202548
202625

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Beleodaq (Belinostat) · HCPCS J9032

2024 spending

$13.5M

Beneficiaries

74

1,352 claims

Per beneficiary

$181,893

2024 ASP limit $49.44 per unit

View as table
YearSpending
2020$8,653,903
2021$5,459,426
2022$9,011,480
2023$10,513,040
2024$13,460,107

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 39 on PubMed

Sponsor: Acrotech Biopharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.